Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,275.00
3,473.00
-1,198.00
-34.49%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,275.00
3,473.00
-1,198.00
-34.49%
Expenditure (Ex Depriciation)
Stock Adjustments
-488.00
7.00
-495.00
-7,071.43%
Raw Materials Consumed
1,868.00
1,505.00
363.00
24.12%
Power & Fuel Cost
2.00
100.00
-98.00
-98.00%
Employee Cost
264.00
423.00
-159.00
-37.59%
Operating Expenses
20.00
153.00
-133.00
-86.93%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
124.00
167.00
-43.00
-25.75%
Cost of Software developments
0.00
8.00
-8.00
-100.00%
Miscellaneous Expenses
31.00
35.00
-4.00
-11.43%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,013.00
2,749.00
-736.00
-26.77%
Operating Profit (PBDIT) excl Other Income
262.00
724.00
-462.00
-63.81%
Other Income
28.00
49.00
-21.00
-42.86%
Operating Profit (PBDIT)
290.00
773.00
-483.00
-62.48%
Interest
4.00
61.00
-57.00
-93.44%
Profit before Depriciation and Tax
286.00
712.00
-426.00
-59.83%
Depreciation
28.00
164.00
-136.00
-82.93%
Profit Before Taxation & Exceptional Items
257.00
547.00
-290.00
-53.02%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
252.00
535.00
-283.00
-52.90%
Provision for Tax
64.00
135.00
-71.00
-52.59%
Profit After Tax
187.00
400.00
-213.00
-53.25%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
632.00
2,891.00
-2,259.00
-78.14%
Profit Available for appropriations
820.00
3,291.00
-2,471.00
-75.08%
Appropriations
820.00
3,291.00
-2,471.00
-75.08%
Equity Dividend (%)
1800%
175%
1,625.00
Earnings Per Share
75.01
16.48
58.53
355.16%
Profit And Loss - Net Sales
Net Sales 2,275.58 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 262.03 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Profit And Loss - Interest
Interest 4.49 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax 187.52 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025






